AL AmyloidosisPhase 2AL-004NCT07751471
BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)
A Phase 2 study testing QLS4131 in people with AL Amyloidosis, run by Institute of Hematology & Blood Diseases Hospital, China at 1 site in China.
Trial summary
Systemic light-chain (AL) amyloidosis is a plasma cell disorder characterized by the production of misfolded immunoglobulin light chains that deposit in organs and lead to progressive organ dysfunction. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- AL Amyloidosis
- What is being tested?
- QLS4131
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteChina
- Study dates
- 20 Jul 2026to 31 Dec 2028
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Voluntarily provide written informed consent (ICF) prior to any study-specific procedures.
- Age ≥18 years, regardless of sex.
- Newly diagnosed primary systemic light-chain (AL) amyloidosis.
- Measurable disease at screening, defined as:
- Difference between involved and uninvolved serum free light chains (dFLC) ≥20 mg/L; and
- Abnormal serum free light chain (FLC) ratio or other confirmed evidence of monoclonal light chain production.
Show all 23Show fewer
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
- Adequate organ function within 3 days before the first administration of the investigational product:
- Absolute neutrophil count (ANC) ≥1.0 × 10⁹/L, without treatment with granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 7 days, and without pegylated G-CSF within 14 days before dosing.
- Hemoglobin ≥75 g/L without whole blood or red blood cell transfusion within 7 days before dosing.
- Platelet count ≥70 × 10⁹/L without platelet transfusion, whole blood transfusion, or thrombopoietin receptor agonists within 7 days before dosing.
- Hepatic function:
- ALT ≤3 × upper limit of normal (ULN);
- AST ≤3 × ULN;
- Total bilirubin ≤2 × ULN. Participants with Gilbert syndrome may be enrolled if direct bilirubin is ≤2 × ULN.
- Coagulation function:
- International normalized ratio (INR) or activated partial thromboplastin time (aPTT) ≤1.5 × ULN.
- Renal function:
- Estimated glomerular filtration rate (eGFR) ≥20 mL/min/1.73 m², calculated using the CKD-EPI equation.
- Male participants, women of childbearing potential, and their partners must agree to use effective contraception during study treatment and for at least 3 months after the last dose.
- Male participants must agree not to donate sperm from screening until 90 days after the last dose of study drug.
- Willing and able to comply with all study procedures and follow-up assessments.
- Women of childbearing potential must have a negative serum or urine β-human chorionic gonadotropin (β-hCG) pregnancy test at screening.
Who cannot join
- Non-AL amyloidosis, including hereditary amyloidosis or any other non-AL subtype.
- Symptomatic multiple myeloma.
- Grade >2 peripheral neuropathy or Grade ≥2 painful peripheral neuropathy at screening, regardless of current treatment.
- History of another malignancy within 5 years before enrollment, except AL amyloidosis.
- Prior anti-plasma cell therapy, including:
- Melphalan
Show all 44Show fewer
- Cyclophosphamide
- Proteasome inhibitors
- Immunomodulatory drugs (IMiDs)
- Monoclonal antibodies
- Bispecific antibodies
- Trispecific antibodies
- Autologous stem cell transplantation
- Chimeric antigen receptor (CAR)-T cell therapy
- Exceptions include:
- Therapy for myeloproliferative neoplasms (e.g., hydroxyurea).
- Chronic corticosteroid therapy (prednisone equivalent ≤20 mg/day) used for conditions such as adrenal insufficiency or rheumatoid arthritis.
- Known hypersensitivity, intolerance, or contraindication to the investigational BCMA/GPRC5D trispecific antibody.
- Unstable or active cardiovascular or cerebrovascular disease, including:
- Unstable angina, symptomatic myocardial ischemia, myocardial infarction, coronary revascularization, transient ischemic attack, subarachnoid hemorrhage, central nervous system hemorrhage, severe brain injury, stroke, seizure, deep vein thrombosis, or pulmonary embolism within 180 days before first dosing.
- Hospitalization for cardiovascular disease within 4 weeks before enrollment in participants with congestive heart failure.
- Heart failure primarily caused by ischemic heart disease or uncorrected valvular disease rather than AL cardiac amyloidosis.
- New York Heart Association (NYHA) Class IV heart failure.
- History of sustained ventricular tachycardia or ventricular fibrillation, or atrioventricular (AV) node or sinoatrial (SA) node dysfunction requiring but not receiving a pacemaker or implantable cardioverter-defibrillator (ICD). Participants with implanted pacemakers or ICDs are eligible.
- Corrected QT interval (QTcF) >500 ms (participants with implanted pacemakers are exempt).
- Supine systolic blood pressure <90 mmHg.
- Any other cardiovascular or cerebrovascular condition considered by the investigator to make study participation inappropriate.
- Symptomatic interstitial lung disease or noninfectious pneumonitis (e.g., pneumoconiosis, radiation pneumonitis, or drug-induced pneumonitis), or pulmonary impairment requiring supplemental oxygen.
- Requirement for oral anti-infective therapy within 2 weeks before first dose or intravenous systemic anti-infective therapy within 4 weeks before first dose.
- Active infection, including:
- Active hepatitis B infection (HBV DNA positive);
- Active hepatitis C infection (HCV RNA positive in participants with positive anti-HCV antibody);
- Human immunodeficiency virus (HIV) infection;
- Active or latent syphilis (positive Treponema pallidum antibody);
- Active pulmonary tuberculosis identified within 3 months before first dose or during screening.
- Pregnant or breastfeeding women.
- Any condition that may interfere with compliance with the study protocol (e.g., substance abuse, dementia, altered mental status), interfere with study procedures or interpretation of results, or pose unacceptable risk according to investigator judgment.
- Active gastrointestinal disorders that impair swallowing or are likely to interfere with study drug absorption.
- Major surgery within 2 weeks before enrollment, incomplete recovery from surgery, or planned major surgery during study participation. Kyphoplasty and vertebroplasty are not considered major surgery. Procedures under local anesthesia are permitted.
- Receipt of a live attenuated vaccine within 4 weeks before the first study drug administration.
- Contraindication to any required concomitant medication or supportive therapy.
- Any disease or medical condition that may interfere with study procedures.
- Unwillingness or inability to comply with the study protocol.
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for study participation.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
jieqiong zhou, PhD contact
China1 site
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020
Gang an, MD, +022-23909083, angang@ihcams.ac.cn
jieqiong zhou, PhD, zhoujieqiong@ihcams.ac.cn
About this study
Official title: A Single-arm Single-center Trial of BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)
Systemic light-chain (AL) amyloidosis is a plasma cell disorder characterized by the production of misfolded immunoglobulin light chains that deposit in organs and lead to progressive organ dysfunction. Although daratumumab-based therapy has improved outcomes, a substantial proportion of patients fail to achieve deep hematologic responses.
This is a prospective, single-arm, single-center clinical study evaluating the safety and efficacy of the BCMA/GPRC5D/CD3 trispecific antibody QLS4131 in patients with newly diagnosed systemic AL amyloidosis.
Read the detailed description
Systemic light-chain (AL) amyloidosis is a rare plasma cell disorder caused by the production of monoclonal immunoglobulin light chains that misfold and deposit in vital organs, resulting in progressive organ dysfunction and poor survival. Rapid suppression of pathogenic plasma cells and achievement of deep hematologic responses are strongly associated with improved organ recovery and survival.
Current first-line treatment based on daratumumab plus cyclophosphamide, bortezomib, and dexamethasone has significantly improved clinical outcomes; however, approximately 40% of patients do not achieve complete hematologic remission, and early mortality remains substantial. Therefore, more effective frontline therapies are needed.
QLS4131 is a novel GPRC5D/BCMA/CD3 trispecific antibody that simultaneously targets two plasma-cell antigens (BCMA and GPRC5D) while redirecting CD3-positive T cells to eliminate malignant plasma cells. Dual-antigen targeting may improve tumor recognition, reduce antigen escape, and enhance antitumor activity without substantially increasing toxicity.
This prospective, single-arm, single-center study will enroll approximately 20 adult patients with newly diagnosed systemic AL amyloidosis. Participants will receive subcutaneous QLS4131 using a step-up dosing schedule followed by maintenance dosing for 6 to 8 treatment cycles.
- Conditions
- AL Amyloidosis
- Being tested
- QLS4131
- Keywords
- QLS4131, Systemic Light Chain Amyloidosis, BCMA/GPRC5D/CD3 trispecific antibody, Plasma cell disorder
- Medical subject headings
- Immunoglobulin Light-chain Amyloidosis, Neoplasms, Plasma Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QLS4131Drug
QLS4131 is an investigational GPRC5D/BCMA/CD3 trispecific antibody administered by subcutaneous injection. The study uses a step-up dosing schedule followed by full-dose maintenance treatment over 6 to 8 treatment cycles. Supportive care and prophylactic medications for cytokine release syndrome (CRS) are permitted according to the study protocol.
| Study group | Role | What they receive |
|---|---|---|
| QLS4131-treatment group | Experimental | Not described Receives: Drug: QLS4131 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hematologic Complete Response (CR) Rate
Proportion of participants achieving hematologic complete response (CR) according to the International Society of Amyloidosis (ISA) response criteria following treatment with QLS4131.
Measured: At the end of each 28-day treatment cycle and before the start of the next cycle, through Cycle 8 （each cycle is 28 days)
Secondary outcomes (7)
time to hematologic response
Time from the first dose of QLS4131 to the first documented hematologic response.
Measured: From the first dose until the first documented response, assessed every 2 weeks in Cycle 1 and every 28 days from Cycle 2 through end of treatment (each cycle is 28 days)
Duration of Hematologic Response (DOR)
Time from first observed hematologic response to disease progression or death due to disease progression, whichever occurs first.
Measured: From first documented response until disease progression or death, assessed up to 2 years
Overall Hematologic Response Rate (ORR)
Proportion of patients achieving a hematologic response of partial response (PR) or better.
Measured: From first dose through end of treatment, assessed every 28 days
Minimal residual disease (MRD) negativity rate
Proportion of patients achieving bone marrow MRD negativity at a sensitivity of 10-⁵.
Measured: Bone marrow MRD assessed at the time of suspected hematologic complete response (CR) or dFLC <10 mg/L, up to the end of treatment from first dose
Progression-Free Survival (PFS)
Time from start of treatment to hematologic progression or death, whichever occurs first.
Measured: From first dose until disease progression or death, assessed up to 2 years
overall survival (OS)
Time from start of treatment to death from any cause.
Measured: From first dose until death from any cause, assessed up to 2 years
organ response
Organ response rate and time to organ response in patients with baseline organ involvement
Measured: From first dose through end of follow-up, up to 2 years.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Aug 2026
- Study start20 Jul 2026 (estimated)
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AL AmyloidosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07751471
- Sponsor's protocol ID
- IIT2026034
- Acronym
- AL-004
- Status last verified
- Aug 2026
- First submitted
- 21 Jul 2026
- Last updated
- 7 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No